Immuron (ASX:IMC) Buyback Yield %: -63.27 (As of Jun. 30, 2026)


What is Immuron Buyback Yield %?

Immuron ASX:IMC -5.71% Buyback Yield % is -63.27 as of Jun. 30, 2026. The stock has 4 warning signs investors should review. Among 742 Biotechnology companies, Immuron ranks worse than 85.71% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Immuron's current buyback yield was -63.27%.

Immuron Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Immuron's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immuron Buyback Yield % Chart

Immuron Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -80.53 0.00 0.00 -0.12 -2.78

Immuron Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.12 0.00 -2.78 -60.79

ASX:IMC vs VRTX, REGN, ALNY: Buyback Yield % Comparison

For the Biotechnology subindustry, Immuron's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immuron Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immuron's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Immuron's Buyback Yield % falls into.


Immuron Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Immuron's Buyback Yield for the fiscal year that ended in Jun. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0.397) / 14.271499
=-2.78%

Immuron's annualized Buyback Yield for the quarter that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 7.149) / 11.759544
=-60.79%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -63.27 mean?
Immuron (ASX:IMC) has a Buyback Yield % of -63.27 as of Jun. 30, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Immuron and its competitors. According to the industry distribution chart, Immuron ranks #636 out of 742 companies in the Biotechnology industry, placing it in the top 85.7%.
Is Immuron's Buyback Yield % too high?
Immuron's current Buyback Yield % is -63.27. Based on the distribution chart, Immuron ranks #636 out of 742 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Immuron's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immuron ranks #636 out of 742 companies for Buyback Yield %. This places Immuron in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Immuron and its competitors. Immuron's current Buyback Yield % is -63.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immuron stock overvalued right now?
Based on GuruFocus' analysis, Immuron (ASX:IMC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.23, compared to a current price of A$0.03 — trading 85.7% below its estimated fair value. The current Buyback Yield % is -63.27. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Immuron (ASX:IMC), the current Buyback Yield % is -63.27 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Immuron Business Description

Other Exchanges IMRN:USAANW:Germany
Address 25-37, Chapman Street, Unit 10, Blackburn, Melbourne, VIC, AUS, 3130
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.